{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematopoietic+Stem+Cell+Transplantation+%28HSCT%29&page=35", "query": { "condition": "Hematopoietic Stem Cell Transplantation (HSCT)", "page": 35 }, "page_size": 10 }, "pagination": { "page": 35, "page_size": 10, "total_count": 2034, "total_pages": 204, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematopoietic+Stem+Cell+Transplantation+%28HSCT%29&page=36&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hematopoietic+Stem+Cell+Transplantation+%28HSCT%29&page=34&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T00:37:15.211Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00582894", "title": "Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hematological Neoplasms", "Hematopoietic Stem Cell Transplantation" ], "interventions": [ { "name": "Busulfex, Fludarabine, ALemtuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 17, "start_date": "2005-02", "completion_date": "2008-03", "has_results": true, "last_update_posted_date": "2011-04-22", "last_synced_at": "2026-10-17T00:37:15.211Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT00582894" }, { "nct_id": "NCT02052570", "title": "School Reintegration After Pediatric Hematopoietic Stem Cell Transplant", "overall_status": "WITHDRAWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Unspecified Complication of Bone Marrow Transplant" ], "interventions": [], "intervention_types": [], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "10 Years to 16 Years" }, "enrollment_count": 0, "start_date": "2014-01", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2015-02-04", "last_synced_at": "2026-10-17T00:37:15.211Z", "location_count": 1, "location_summary": "Durham, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02052570" }, { "nct_id": "NCT05993611", "title": "Allogeneic CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) for the Treatment of Patients With Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Graft Versus Host Disease", "Hematologic and Lymphocytic Disorder", "Steroid Refractory Graft Versus Host Disease" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography", "type": "PROCEDURE" }, { "name": "Electronic Health Record Review", "type": "OTHER" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Tafasitamab", "type": "BIOLOGICAL" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "OTHER" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2024-02-19", "completion_date": "2028-05-21", "has_results": false, "last_update_posted_date": "2025-11-13", "last_synced_at": "2026-10-17T00:37:15.211Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05993611" }, { "nct_id": "NCT00578292", "title": "Allogeneic Stem Cell Transplantation, Severe Homzygous 0/+Thalassemia or Sever Variants of Beta 0/+ Thalassemia, THALLO", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Thalassemia" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Campath 1H", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "MESNA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "64 Years", "sex": "ALL", "summary": "Up to 64 Years" }, "enrollment_count": 10, "start_date": "2004-02", "completion_date": "2016-05", "has_results": true, "last_update_posted_date": "2020-05-01", "last_synced_at": "2026-10-17T00:37:15.211Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00578292" }, { "nct_id": "NCT02663622", "title": "Phase II Trial of Efprezimod Alfa (CD24Fc, MK-7110) for the Prevention of Acute Graft-Versus-Host Disease (GVHD) Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-002)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease", "Hematopoietic Stem Cell Transplantation", "Leukemia" ], "interventions": [ { "name": "Efprezimod alfa", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 44, "start_date": "2016-09-19", "completion_date": "2021-05-18", "has_results": true, "last_update_posted_date": "2024-01-23", "last_synced_at": "2026-10-17T00:37:15.211Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Ann Arbor, Michigan • Detroit, Michigan + 1 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02663622" }, { "nct_id": "NCT03807063", "title": "Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Bilineal Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Myeloproliferative Neoplasm", "Recurrent Acute Biphenotypic Leukemia", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Acute Myeloid Leukemia", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Myelodysplastic Syndrome" ], "interventions": [ { "name": "Rivogenlecleucel", "type": "BIOLOGICAL" }, { "name": "Rimiducid", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": null, "sex": "ALL", "summary": "12 Months and older" }, "enrollment_count": 0, "start_date": "2020-01-02", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2020-08-14", "last_synced_at": "2026-10-17T00:37:15.211Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT03807063" }, { "nct_id": "NCT01235793", "title": "The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "B-Cell Lymphoma Originating in the CNS" ], "interventions": [ { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cedars-Sinai Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 11, "start_date": "2010-10-14", "completion_date": "2018-04-18", "has_results": true, "last_update_posted_date": "2018-11-20", "last_synced_at": "2026-10-17T00:37:15.211Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01235793" }, { "nct_id": "NCT00453206", "title": "Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 66, "start_date": "2007-02", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2018-09-10", "last_synced_at": "2026-10-17T00:37:15.211Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00453206" }, { "nct_id": "NCT02470104", "title": "Donor Human Milk in Young Children Receiving Bone Marrow Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Bone Marrow Transplant - Autologous or Allogeneic" ], "interventions": [ { "name": "Breastmilk", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DIETARY_SUPPLEMENT" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "4 Years", "sex": "ALL", "summary": "Up to 4 Years" }, "enrollment_count": 42, "start_date": "2015-03", "completion_date": "2018-05-04", "has_results": false, "last_update_posted_date": "2020-08-20", "last_synced_at": "2026-10-17T00:37:15.211Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02470104" }, { "nct_id": "NCT03537963", "title": "Improving Sleep in BMT Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Sleep Disturbance", "Sleep Disorder" ], "interventions": [ { "name": "mHealth Stepped-care Intervention", "type": "OTHER" }, { "name": "Educational Control Condition", "type": "OTHER" }, { "name": "Questionnaire", "type": "OTHER" }, { "name": "Interview", "type": "OTHER" }, { "name": "Qualitative Interviews", "type": "OTHER" }, { "name": "Virtual Reality", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2018-05-15", "completion_date": "2024-04-19", "has_results": false, "last_update_posted_date": "2026-02-06", "last_synced_at": "2026-10-17T00:37:15.211Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03537963" } ] }